Physician profile
John Cozzarelli
NPI 1699889535
$932,013.42
in general payments reported to CMS, 2019-2025
20 companies · $99K in 2025
The $99K reported for 2025 was more than what 99% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142K · 2020: $47K · 2021: $94K · 2022: $162K · 2023: $198K · 2024: $190K · 2025: $99K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $221K · Honoraria: $143K · Travel and Lodging: $103K · Food and Beverage: $15K · Consulting Fee: $5,625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $220,750.00 |
| Honoraria | $143,481.00 |
| Travel and Lodging | $102,632.37 |
| Food and Beverage | $14,641.26 |
| Consulting Fee | $5,625.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $642,128.51 | 2019-2023 | Krystexxa |
| Amgen INC. | $285,705.92 | 2024-2025 | Krystexxa |
| Sobi, INC | $2,727.44 | 2025 | |
| Ani Pharmaceuticals, INC. | $284.61 | 2022-2025 | Purified Cortrophin Gel |
| Paratek Pharmaceuticals, INC. | $274.22 | 2021-2025 | Nuzyra |
| Treace Medical Concepts, INC. | $153.75 | 2022-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $151.07 | 2019-2022 | |
| Abbvie INC. | $147.81 | 2021-2023 | Dalvance |
| Alfasigma USA, INC. | $136.05 | 2020-2022 | |
| Sebela Pharmaceuticals INC. | $65.78 | 2020-2023 | Naftin |
| Hikma Pharmaceuticals USA | $63.87 | 2019-2022 | |
| Integra Lifesciences Corporation | $35.53 | 2019 | |
| Nevro Corp. | $24.97 | 2021 | |
| Zimmer Biomet Holdings, INC. | $23.49 | 2021 | |
| Organogenesis INC. | $17.52 | 2023 | Puraply |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axogen | $16.67 | 2022 | |
| Davol INC. | $15.29 | 2020 | |
| Assertio Therapeutics, INC. | $14.25 | 2020 | |
| Zyla Life Sciences, INC. | $14.17 | 2020 | |
| Nabriva Therapeutics, Plc | $12.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cozzarelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.